25G玻璃体切除治疗上方孔源性视网膜脱离的疗效

目的 研究25G玻璃体切除联合空气填充治疗上方孔源性视网膜脱离的临床治疗效果及安全性。 方法 回顾性分析2018年12月至2020年3月行25G玻璃体切除联合空气填充的上方孔源性视网膜脱离的患者32例32眼。观察术前及术后1周、末次随访时间的最佳矫正视力(LogMAR)、眼压、视网膜复位情况及并发症。 结果 术前视力(BCVA, LogMAR)1.4(0.2-1.7),术后1周平均视力0.83±0.35,末次随访平均视力0.52±0.34,术前与术后视力差异有统计学意义(Mann Whitney U 检验,P<0.05),术后视力明显提高。术前平均眼压(15.15±3.04)mmHg,术后1周平均眼压(17.75±2.75)mmHg,差异有统计学意义(P<0.05),术后一周眼压较术前眼压升高。末次随访平均眼压15.20±1.81 mmHg,与术前比较无统计学差异(P>0.05)。末次随访时32例患者视网膜全部复位,复位率100%。3例患者发生术后一过性眼压升高,2例患者晶体发生羽毛状混浊,均恢复正常。 结论 玻璃体切除联合空气填充治疗上方孔源性视网膜脱离安全有效,并发症少,成功率高,可以作为治疗上方孔源性视网膜脱离的一种有效手术方式。

Surgical clinical treatment outcomes of 25 gauge vitrectomy for superior rhegmatogenous retinal detachment with air tamponade

Objective To observe the clinical treatment outcomes and safety of 25-gauge vitrectomy with air tamponade for superior rhegmatogenous retinal detachment. Methods Retrospective analysis 32 eyes with superior rhegmatogenous retinal detachment from 32 patients who received 25-gauge vitrectomy with air tamponade from December 2018 to March 2020. Best corrected visual acuity(BCVA)(LogMAR)and intraocular pressor(IOP)were test before surgery, 1 week, and the last follow-up time after surgery. Retinal reattachment condition and intraoperative and postoperative complications were recorded. Results The mean BCVA was significantly different among before surgery,1 week and the last follow-up time after surgery,and the BCVA at 1 week and the last follow-up time after surgery was evidently improved in comparison with before surgery(1.4(0.2-1.7), 0.83±0.35, 0.52±0.34, Mann Whitney U text, P<0.05).The mean IOP was(15.15±3.04 mmHg)before surgery and(17.75±2.75 mmHg)1 week after surgery, showing a significant difference among them(t text, P<0.05), the IOP 1 week after surgery was evidently higher than that before surgery.The mean IOP was(15.20±1.81 mmHg)at the last follow-up time, have not difference between the mean IOP before the surgery(t text, P>0.05). The retinal reattachment rate following a single procedure was 100%. Conclusion 25-Gauge vitrectomy and air tamponade for superior rhegmatogenous retinal detachment is an effective and safe approach, and fewer complications and higher success rates.